Your contact persons

CHEPLAPHARM Arzneimittel GmbH

Mysimba®: Commercialization and distributorship arrangement with Orexigen Therapeutics Ireland, Ltd.

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement covering Germany, France and Austria for Mysimba® (naltrexone HCl / bupropion HCl prolonged release).

Under the terms of the agreement, CHEPLAPHARM will be responsible for all commercialization activity and expenses. Orexigen will supply Mysimba® to CHEPLAPHARM for a negotiated transfer price.

"CHEPLAPHARM’s strong capabilities in weight management therapy and established relationships in the market make them an ideal partner to bring Mysimba® to patients in Germany, France and Austria," said Dr. Thomas Canell, EVP, Chief Operating Officer and President of Global Commercial Products of Orexigen. "With this agreement, we now have partnerships covering 48 countries worldwide. In Europe, Mysimba® has now launched in 16 countries, and we expect to launch in up to eight more countries by year end."

"We are excited about our partnership with Orexigen and are dedicated to using our experience to help bring Mysimba® to patients struggling with their weight and obesity in Germany, France and Austria," said Sebastian F. Braun, CHEPLAPHARM‘s Chief Executive Officer.

Obesity and related comorbidities are a significant health problem across Europe, including the combined population of 150 million people in Germany, France and Austria. The percentage of the adult population struggling with obesity in these countries is: Germany (20%), France (18%) and Austria (21%), which represents a significant number of individuals in these large markets. On average, more than 50% of the adult population in these countries are overweight (Source: Kompetenzzentrum Adipositas; IGES Institut; Weißbuch Adipositas, DAG, World Bank).

Press office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)


Back to top expand_less